To investigate the feasibility of in vivo proton magnetic resonance spectroscopy (MRS) for evaluation of lung cancer.
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Lung cancer is currently the leading cause of cancerspecific death worldwide, with a death toll greater than breast, prostate and colorectal cancer combined (1) . However, at the time of diagnosis, over 75% of persons with lung cancer have loco-regional spread or distant metastases, substantially reducing the chance of survival (2) . Thus, in patients with inoperable lung cancer, radiation therapy and chemotherapy are the most common treatment strategies employed. In order to optimize and avoid ineffective treatment, there is a critical need for the early evaluation of response to these treatments as well as early and precise prediction of survival probabilities, which will facilitate more appropriate therapeutic planning in patients with lung cancer. 
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tools. Among them, in vivo proton magnetic resonance spectroscopy (MRS) which has been proven to provide additional information in characterizing and detecting the cellular chemistry of most brain tumors (3, 4) , prostate (5), breast (6) , and uterine cervix (7) , is one of the most promising imaging tools for monitoring the treatment response of lung cancer to radiation therapy, or chemotherapy, or for screening patient populations with certain types of cancer treatment.
Previous studies dealing with in vitro proton MRS of the lung have shown higher levels of lactate at 1.3 ppm and choline-containing compounds at 3.2 ppm in lung cancer than in normal lung parenchyma (8) (9) (10) (11) . However, in vivo detection of choline using absolute measurement methods have not been easy due to variations in signal amplitudes measured in the lesions and the reference owing to magnetic field inhomogeneities which lead to uncertainties in concentration estimation (12) . In addition, due to lung motion, performance of a spectroscopic examination with an absolute concentrations protocol required a considerable period of time.
Most recently, an acquisition and detection method for MRS using the point-resolved spectroscopic (PRESS) sequence has been introduced and proved to be sufficiently sensitive while requiring less time in MRS of breast (13) or liver tumors (14) . However, to the best of our knowledge, there have been no studies regarding in vivo proton MRS of lung cancer. Therefore, the purpose of the present study was to investigate the feasibility of in vivo proton MRS for evaluation of lung cancer.
This prospective study was approved by the institutional review board of our hospital and informed consent was obtained from all patients prior to MR examination.
Study Population
Between June 2007 and March 2009, 10 patients (7 men and 3 women; mean age, 64.4 years; age range, 44-77 years) with alleged lung cancer 40 mm or more (mean diameter, 56.8 mm, diameter range, 44-77 mm) were included in this prospective MRS study. The patients with alleged lung cancer less than 40 mm were excluded as the acquisition of MRS data was expected to be easily failed considering the cardiorespiratory movement of alleged lung cancer.
MRI Technique
All MRI and proton MRS were performed using a whole-body 1.5-T scanner (General Electric EXITE HD, Milwaukee, WI) with a built-in body coil. Our chest MR protocol consisting of fast spin-echo T2-weighted (TR 611.3 msec, TE 86.7 msec, slice thickness 7 mm, slice gap 8.4 mm), three dimensional fast spoiled gradient echo fat-saturated T1-weighted (FSPGR; TR 4.1 msec, TE 2.0 msec, slice thickness 5 mm, slice gap 2.5 mm), and contrast-enhanced dynamic three-dimensional FSPGR T1W axial imaging was performed prior to acquisition of spectroscopic data to localize the lung mass. Localizing images for spectroscopic data acquisition was acquired by a spinecho sequence (TR/TE, 350/30 msec; matrix size, 256 ×256; number of excitations, 1). Single-voxel MRS using the point resolved spectroscopy sequence (PRESS) was done with repetition time (TR) varying according to patients' respiration rate from 2050 to 3000 msec; echo time of 30 msec; number of excitations, 96; voxel size, 10×10×10 mm; spectral width, 2500 Hz; and 2048 data points. Total acquisition time for each MR spectrum was 10 to 12 minutes including localization, pre-scan for shimming and other parameter adjustments, and real spectral acquisition ranging from 4.8 to 8.6 minutes. Location of a voxel of interest (VOI) was determined by one experienced radiologist (C.H.L. with 6 years of experience in chest MR imaging). Based on noncontrast T2-weighted, T1-weighted and contrast-enhanced MR images, the largest homogenously enhancing solid portion of lung tumors was chosen, with attention paid to avoid inclusion of necrotic or cystic portions. Each patient was explained by the techniques of shallow and regular breathing prior to the procedure and these techniques were maintained during MRS data acquisition.
MR Image and Spectra Analysis
All MRIs of lung tumors were assessed by one chest radiologist (C.M.P. with 4 years of experience in chest MR imaging) and one MR physicist (I-C. S. with 15 years of experience in MRS) blinded to MR imaging
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features and clinical data. MRS data were analyzed using commercially available software (SAGE 7.2, GE Medical Systems). All spectra were processed with 5-Hz Gaussian apodization and zero-filled to 4096 points.
We also assessed the technical success rate and investigated the reason of technical failure, if any, in those cases. MR spectra were defined to be analyzable quality if the line width of lipid peak at 1.2 ppm was less than 30 Hz after 5 Hz line broadening in spectral post-processing. Criteria for determining whether choline and lactate resonance was present were the peak at 3.2 ppm for choline and 1.3 ppm for lactate with a line width less than 15 Hz and signal-to-noise ratio (SNR) greater than 3. Spectra that revealed no significant choline or lactate resonance but met the criteria for analyzable quality were included. Those with serious baseline distortion impeding the recognition of lipid resonance, a broad lipid line width, or no observable lipid resonance were excluded from analysis. The choline-to-lipid ratio was measured by dividing the peak area of choline at 3.2 ppm by the peak area of lipid at 1.2 ppm.
All patients (n = 10) were finally diagnosed with lung cancer, i.e., squamous cell carcinoma (n = 4), adenocarcinoma (n = 3), small cell carcinoma (n = 2), and adenoid cystic carcinoma (n = 1) histopathologically from specimens obtained by lobectomy (n = 3), pneumonectomy (n = 2), percutaneous biopsy (n = 3), and bronchoscopic biopsy (n = 2). The mean duration between the pathologic diagnosis and the MR scans was 7.8 days (range: 1 ~ 35 day). Three lesions were located in the left upper lobe, three in the left lower lobe, two in the right middle lobe and two in the right lower lobe. Table 1 summarizes the MR spectroscopic findings of lung cancers in the 10 patients. Among the 10 lung cancers, spectra of analyzable quality were obtained in 8 tumors (technical success rate, 80%). Two MRS datasets could not be analyzed due to serious baseline distortion. Among the eight patients with analyzable MR spectra, resonance at 3.2 ppm attributed to a choline-containing compound was detected in four patients (two patients with adenocarcinoma, one with small cell carcinoma and one adenoid cystic carcinoma, Figure 1 ). In the remaining four patients (three patients with squamous cell carcinoma, and one with small cell carcinoma), a choline peak was not detected. Lactate was not detected in any patient. Mean choline SNR of lung cancers was 10.0 14.4 (range, 0 -31.2). Mean lipid SNR of lung cancers was 152.1 97.7 (range, 11.1 -290.0). The mean choline-to-lipid ratio of lung cancers was 0.2 0.34 (range, 0 -0.96). All negative findings were confirmed based on the absence of any identifiable signal at 3.2 ppm for choline and 1.3 ppm for lactate above the baseline noise on the spectra. The main findings obtained in our preliminary study were that we successfully obtained analyzable in vivo MRS spectra of lung cancer in most patients and that choline compounds were detected in a limited number of patients. In vivo MRS of lung cancer has been rarely attempted due to the various technical difficulties including compromised localization on MRS using the stimulated-echo acquisition mode. However, the PRESS sequence with continued respiration-triggered acquisition as we have experienced was able to overcome these difficulties in part and provided analyzable spectra within 10-12 minutes using a clinical MR scanner.
RESULTS
There were two failure cases having serious baseline distortion on MRS spectra. The mean size of lung cancers in failure cases was similar with that in success cases (mean size, 57.5 mm vs. 56.6 mm). We failed to find any specific tendency in the tumor location or pathologic subtype of failure cases compared to those of success cases. The possible cause of failure in acquiring analyzable spectra was a intratumoral heterogeneity. Although we did not analyze a tumor texture quantitatively, T2 signal intensity of lung cancer in failure cases was visually more heterogeneous than that in success cases. Given that a loss of homogeneity leads to inconsistent acquisition of MRS spectra (15) , the intratumoral inhomogeneity of lung cancer may increase a baseline noise and disturb an accurate acquisition of peak height of metabolites.
In this study, choline was detected in four of the eight patients with analyzable MRS spectra. Cholinecontaining compounds are known to be involved in both the synthesis and degradation of cellular membranes. Previous in vitro MRS studies revealed that choline could be detected in the extracts of both normal lung parenchyma and lung cancer, with lung cancer showing higher concentrations than normal lung parenchyma (9-11). Even though cholinecontaining compounds could be detected either in lung parenchyma or in lung cancer on in vitro MRS, the detected choline SNR in our study was thought to be truly detected within lung cancer rather than lung parenchyma considering following two aspects. First, MRS data was acquired within a voxel confined to the tumor using continued respiration-triggered acquisition. Additionally, in regard to lung parenchyma, MR signal of in vivo lung parenchyma could not be easily detected not only due to the low proton density of lung parenchyma compared to that of tissue extract, but also due to the predominant field inhomogeneity of lung parenchyma. The SNR of lung cancer in our study was relatively high when it was compared with malignancies in other sites (16) . The current result leads us to conclude that in vivo analysis of tumor metabolites using MRS may possibly be introduced for lung cancer along with the most advanced MRS technique to date which may overcome the preexisting limitations of MRS. Lactate, the end product of anaerobic glycolysis, is known to reflect tumor glucose metabolism. According to earlier researches (9, 17) , lactate might be more useful than choline in predicting the prognosis of lung cancer. However, in the present study, although we tried to avoid placing the VOI in a nonviable portion of lung cancer such as a cystic or necrotic area by reviewing the contrast enhanced MR images, lactate was not detected in any enrolled patient. Even though contrast material within voxel may affect the acquisition of MRS signal, we do not believe that it is significant based on the results of the previous study (18) . When we reviewed the analyzable MR spectra, lipid peak tended to be widened even though there were variations in their degrees. Given that the resonance peak of lactate and lipid is close, lipid signals may hinder the detection of lactate signals if the lipid peak is widened. Our observation is similar to the concern of Yokota et al. in that lipid signals could overlap and hinder the lactate signal on in vivo MRS (9) . This result suggests that the detection of lactate remains a challenge with the current in vivo MRS technique.
One possible cause of failure in detecting choline and lactate is the field-strength of MR. Considering that MRS at 3.0 T increases the SNR of chemical compounds as well as chemical shift dispersion in comparison with MRS at 1.5 T (19), the detectability of choline compounds and lactate may be improved using the higher field-strength of 3.0 T MR. However, given that higher field strength increases field inhomogeneity which is one of the major problems of chest MR, it is not conclusive whether 3.0 T MR would improve the detectability of a trace amount of chemical compounds on chest MRS. Further study is warranted to address this issue.
The error of peak height of metabolites in spectra can be caused by variable enlongations of TR ranging from 2050 to 3000 msec in this study as compared with that of conventional PRESS (1500 msec). The variably enlongated TR according to patients' respiration rate is somewhat inevitable as the lack of use of respiratory triggering results in trouble acquiring analyzable spectra in MRS for evaluating lung parenchymal lesions. These errors may be overcome by the postprocessing that gathers and analyzes the spectra with similar TRs among patients after multiple acquisition of MR spectroscopic data.
Respiratory and cardiac movements are supposed to hinder the detection of small amounts of metabolites within lung cancers (20) . Given that the maximum three-dimensional movement of lung cancer was up to approximately 2 cm at normal respiration (21), 10 mm 3 sized voxels might be transiently off the initially chosen location, or further the boundary of lung cancer during the acquisition of MRS data despite of continued respiration-triggered acquisition. Additionally, the respiratory movement of lung cancer might be intensified by the heartbeat of patient although the impact of heartbeat depends on how the lung cancer is close to heart (16). During cardiopulmonary movement, not only change of tumor tissue within the voxel but also change of surrounding tissues around the voxel may make the SNR of metabolites less significant.
Interestingly, lipid was detected in all patients with analyzable MRS spectra in our study. Based on in vitro MRS results, the concentration of lipid was higher in lung cancer than normal lung tissue (10, 11) . Considering the paucity of lipid in normal lung parenchyma, the detection of lipid peak within the tumor on in vivo MRS might play a role in the evaluation of lung cancer. However, prior to interpretation of the significance of lipid peak, further investigation is required regarding whether the lipid signal on MRS was contributed by necrotic component within the tumor or by non-necrotic tumor component itself.
Considering the results of recent observations of ex vivo MRS in tissue metabolites of human lung cancers, in vivo MRS is expected to have a role in predicting benignity or malignancy of parenchymal lung lesion. There has been consistent results reporting the elevation of lactate, choline materials including phosphocholine, glycerophosphocholine and the reduction of glucose, acetate, myo-inositol and etc (8) (9) (10) (11) 22) . Furthermore, the differences between histologic subtype of lung cancer were also observed in ex vivo MRS (10) . If the pre-existing difficulties in in vivo MRS for evaluating lung cancer can be overcome, MRS can be used widely beyond current morphologic evaluation of lung cancer in the future.
There are some limitations in the present study. First, it is limited by a relatively small number of enrolled patients. Second, the pathologic diagnoses of lung cancer were heterogeneous. However, this may have been to some degree inevitable as the patients were prospectively enrolled prior to a pathologic diagnosis. Third, inflammatory lesions or benign neoplasms were not included as a control in this study. If included, the undertone of choline to lipid ratio might be assessed with regards to differentiating malignancies from benign lesion. However, we had focused lung cancer which is known to show an abnormal peak of choline and lactate on MRS, as the goal of our study was to investigate the technical feasibility of in vivo MRS in detecting metabolites within lung cancers.
In conclusion, in vivo proton MRS using the PRESS sequence with continued respiration-triggered acquisition is feasible but provides limited information in the evaluation of large (> 40 mm in diameter) lung cancers in regards to choline detection. In vivo acquisition of metabolite concentration in lung cancer may aid in tumor characterization even though it currently still remains challenging. Further studies using other sequences such as multivoxel MRS, averaging TE technique (23), or short echo time MRS (24) will be needed in order to improve the detection of chemical compounds. 
